PLAINSBORO, N.J., March 26, 2018 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration
Blood sugar control between the two groups was similar at baseline and throughout the trial.1 In DEVOTE, severe hypoglycemia was defined as having a low blood sugar level that requires assistance from another person to treat.
[For patients seeking information on Tresiba®, please visit Tresiba.com. Healthcare providers seeking clinical information can visit TresibaPro.com]
"Tresiba® is clinically proven to lower patients' A1C levels, and now the updated label provides physicians with additional clinical evidence to help guide treatment decisions," said Todd Hobbs, vice president and US chief medical officer of Novo Nordisk. "Cardiovascular disease and severe hypoglycemia are two of the most profound concerns for people living with diabetes. Novo Nordisk is dedicated to research in these areas and believes in their importance to overall diabetes care."
About DEVOTE DEVOTE is a multi-national, randomized, double-blinded, treat-to-target, event-driven trial comparing Tresiba® (insulin degludec injection) U-100 to insulin glargine U-100. In the trial, 7,637 people (Tresiba® U-100: n=3,818, insulin glargine U-100: n=3,819) with inadequately controlled type 2 diabetes and atherosclerotic cardiovascular disease were randomized to once daily treatment with either Tresiba® U-100 or insulin glargine U-100 in addition to standard of care for diabetes and cardiovascular disease for a median duration of 2 years.
The primary composite endpoint in DEVOTE was time from randomization to the first occurrence of a three component composite major adverse cardiovascular event, comprised of: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Secondary endpoints included events and incidence of severe hypoglycemia.
About Tresiba® Tresiba® is the only long-acting insulin approved for type 1 and type 2 diabetes in children as young as 1 year of age. Once-daily Tresiba® is available in Novo Nordisk's latest insulin delivery device – FlexTouch®, a 100 units/mL or 200 units/mL pen. Tresiba® U-100 FlexTouch® can deliver up to 80 units of insulin in a single injection. Tresiba® U-200 FlexTouch® can dose up to 160 units in a single injection. FlexTouch® is also the only prefilled insulin pen with no push-button extension.
Tresiba® received its first regulatory approval in Japan in September 2012 and has since been approved in more than 80 countries globally. It was approved by the FDA in the United States on September 25, 2015.
What is Tresiba®?
Do not share your Tresiba® FlexTouch® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Who should not take Tresiba®?
Do not take Tresiba® if you:
Before taking Tresiba®, tell your health care provider about all your medical conditions, including if you are:
Talk to your health care provider about low blood sugar and how to manage it.
How should I take Tresiba®?
What should I avoid while taking Tresiba®?
What are the possible side effects of Tresiba®?
Tresiba® may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Common side effects may include reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, and swelling of your hands and feet.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please see Prescribing Information for Tresiba® at http://www.novo-pi.com/tresiba.pdf.
About Diabetes In the United States, more than 30 million people are affected by diabetes.9 Type 2 diabetes specifically affects more than 28 million people in the United States (9.4 percent of the population).9 The diagnosis is most common in adults and occurs when the body no longer produces enough of the blood sugar-regulating hormone, insulin, or is no longer able to use the insulin the body produces properly. Additionally, people with type 2 diabetes are two to four times more likely to have cardiovascular disease than those without diabetes.10 Type 2 diabetes is a life-long condition once diagnosed, but can be managed through a combination of lifestyle modifications like eating healthy, physical activity and oral and/or injectable medications as prescribed by a physician.11
About Novo Nordisk Novo Nordisk, a global healthcare company, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in four states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk.us, Facebook and Twitter.
Tresiba® is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners.
© 2018 Novo Nordisk All rights reserved. USA18TSM00951 March 2018
View original content:http://www.prnewswire.com/news-releases/fda-approves-inclusion-of-data-from-safety-outcomes-trial-in-the-tresiba-label-300619368.html
SOURCE Novo Nordisk
Subscribe to our Free Newsletters!